NAD+ Offers: The Legal Line Between Supplement, Injection, and Drug

Is NAD+ legal to sell as a dietary supplement?

Yes — as a capsule, powder or oral spray, plain NAD+ generally clears the closed list of dietary-ingredient categories under 21 U.S.C. 321(ff)(1), the same statute that lets amino acids and dietary substances qualify while shutting out synthetic non-food molecules, per the Cornell Legal Information Institute's text of the law. That's the funnel most affiliates run inside NAD+ supplement offers rather than a prescription product.

The label's disclaimer doesn't decide the outcome, though. Under 21 CFR 201.128, intended use is 'the objective intent of the persons legally responsible for the labeling' and can be shown by advertising, marketing context or the circumstances of distribution — not by a boilerplate disclaimer, per the Cornell Legal Information Institute's current text of the rule. A capsule marketed with mechanism-of-action language borrowed from injectable-drug studies risks the same reclassification FDA applied to peptide sellers who called their product 'research use only.'

FDA has not issued a comparable written ruling on plain NAD+ the way it has on NMN, so the capsule market's legal footing rests on inference from the closed-list statute rather than a specific agency decision. Treat that as a gap worth tracking, not a settled fact.

Why are NAD+ injections and IV drips regulated as drugs?

Because injectable NAD+ sits on FDA's list of bulk drug substances nominated for compounding, not on any dietary supplement list. 'Nicotinamide Adenine Dinucleotide (NAD)' and NADH both appear in Category 1 — substances under evaluation — on the 503A bulks list FDA updated May 14, 2026, meaning an injected or IV-dripped dose is legally a compounded drug requiring a prescription and a licensed pharmacy or physician.

Category 1 listing is not approval. It buys interim enforcement discretion while FDA evaluates the substance, the same provisional status BPC-157 held before its nomination was withdrawn in April 2026, at which point it dropped out of consideration entirely. A pharmacy compounding NAD+ injections today is operating inside a temporary safe harbor, not a permanent legal green light.

Route of administration, not the molecule, frequently decides the outcome. FDA's own May 2026 bulks list treats topical GHK-Cu one way and injectable GHK-Cu another — the injectable nomination was withdrawn over immunogenicity risk while the non-injectable form went back onto Category 1 — the same delivery-format split that separates an NAD+ capsule from an NAD+ drip.

Where does the FDA's NMN supplement dispute stand?

FDA reversed itself on NMN in September 2025, and the reversal is real but incomplete. In two letters dated September 29, 2025, the agency concluded that beta-nicotinamide mononucleotide is not excluded from the dietary supplement definition under section 201(ff)(3)(B), undoing the November 2022 exclusion that had treated NMN as precluded by prior drug-investigation status, per Venable LLP's summary of the letters.

The reversal doesn't mean NMN is unregulated. FDA still classifies it as a New Dietary Ingredient, so a seller needs an NDI notification on file — a self-affirmed GRAS determination doesn't substitute for one. And because the agency reached this conclusion through interpretive letters rather than rulemaking, a court could revisit it post-Loper Bright, when courts no longer defer automatically to agency readings of ambiguous statutes.

Anyone building past the capsule, stacking NAD+ with NMN or bundling either with an injectable line, should treat that uncertainty as part of the broader longevity and NAD+ offer market, where each SKU's regulatory status has to be checked on its own rather than assumed from the category.

What anti-aging claims can a longevity product lawfully make?

A longevity product can lawfully claim to support a normal body function — cellular energy production, healthy aging, NAD+ levels — as long as the label carries the required disclaimer and the claim stops short of disease language. Under 21 CFR 101.93, that disclaimer must read 'This statement has not been evaluated by the Food and Drug Administration...' in boldface no smaller than one-sixteenth inch, and the marketer must notify FDA's Office of Dietary Supplement Programs within 30 days of first shipping a product bearing a structure/function claim.

The same appearance-versus-function line runs through topical anti-aging claims. FDA has said a product that makes lines 'less noticeable... by moisturizing the skin' is a cosmetic, while one that claims to 'remove wrinkles or increase the skin's production of collagen' is a drug, the exact distinction a longevity brand needs when writing copy for an NAD+ serum instead of a capsule. Any claim beyond the disclaimer boilerplate also needs FTC-grade evidence: 'competent and reliable scientific evidence,' which the FTC's Health Products Compliance Guidance says generally means randomized, controlled human trials, not a citation to cell-culture data.

When does a longevity claim become a disease claim?

A longevity claim becomes a disease claim the moment it implies the product substitutes for, augments or manages the effects of an actual therapy. Under 21 CFR 101.93(g)(2), a supplement crosses that line if it claims to be 'a substitute for a product that is a therapy for a disease,' to 'augment a particular therapy or drug action' meant to treat disease, or to treat, prevent or mitigate 'adverse events associated with a therapy for a disease' — language that turns an ordinary structure/function claim into an unapproved drug claim.

Naming a prescription drug makes the risk concrete. FDA's rule at 101.93(g)(2)(iv)(B) treats it as a disease claim when a supplement contains an ingredient 'well known to consumers for its use... in preventing or treating a disease,' and the agency says it will weigh the surrounding context, which is exactly the trap in NAD+ copy that promises to ease 'Ozempic fatigue' or counter GLP-1 side effects. Some VSLs claim an NAD+ drip offsets semaglutide's nausea or muscle loss; that's a disease-adjacent claim about a named drug's adverse events, not a wellness claim, however the copy is dressed.

This isn't unique to NAD+. The same implied-disease-claim test governs blood pressure supplement offers that promise to 'support what your medication is already doing' — any claim referencing a named condition's treatment, even indirectly, invites the same reclassification.

How do ad platforms treat injectable-wellness marketing?

Every major platform treats injectable-wellness marketing as restricted, not simply available. Meta, Google and TikTok each require some form of licensing or certification before an ad running prescription or near-prescription language reaches users, and each reviews the landing page alongside the ad creative — meaning a compliant ad linking to an aggressive landing page still gets rejected.

Copying a rival's injectable-wellness ad doesn't dodge these gates, either. Google's Abusing the ad network policy separately bans 'evasive ad content' — manipulating text, images or domains to bypass detection — and Meta enforces the same intent under its Account Integrity standard now that its old circumvention page no longer exists as a stand-alone policy. Before lifting an angle from a competitor's NAD+ funnel, it's worth checking whether copying a competitor's ad is actually legal, since platform risk and IP risk run on separate tracks.

Which longevity positioning survives both FDA and FTC review?

The positioning that survives both agencies is narrower than most funnels want: a structure/function claim about a measurable biological process, backed by human data, with the disclaimer present and no reference to any named disease or prescription drug. 'Supports cellular NAD+ levels' clears the bar structure/function claims are built for; 'reverses aging' or 'works like an NAD+ drip without the needle' does not, because FTC's Health Products Compliance Guidance treats a disclaimer as ineffective against a claim that contradicts it in the same breath.

The assumption that physician supervision de-risks the injectable side of the business doesn't hold up as cleanly as most operators believe. State attorneys general have gone after IV clinics directly: Alabama's suit against Aurora IV and Wellness ended in a permanent closure, roughly $24,000 in damages and penalties, and a surrendered nursing license, while Connecticut issued cease-and-desist letters on corporate-practice-of-medicine grounds, stating flatly that 'non-healthcare providers cannot legally own or operate clinics that provide medical care.' Those specific cases targeted peptide compounding rather than NAD+, but the underlying theories, deceptive trade practices and unlicensed clinical control, apply to any Category 1 substance sold through a management-services structure, and new laws like Oregon's SB 951 and California's SB 351 are tightening that structure further in 2025-2026.

None of that makes the oral capsule automatically safer than the injectable drip. It just means the two failure modes are different: the capsule risks an FTC or FDA claims letter over what the label says, while the injectable risks an AG suit or medical-board action over who's legally allowed to run the clinic, on top of the same claims exposure.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Nutra niche intelligence directory, Lung and Respiratory Offers: Small Market, Steep Claim Ceiling, Inflammation Offers: The Umbrella Angle Everyone Borrows, Bone Density Offers: Market, Buyer, and the Osteoporosis Line, Sinus and Allergy Offers: Seasonal Demand, Drug-Category Competition, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.